Clinical characteristics
| Melanoma | HNSCC | |
| Patients | 14 | 6 |
| Male/Female (%) | 10/4 (71/29) | 6/0 (100/0) |
| Median age (range) | 66 (38–45) | 61 (41–69) |
| BRAF mutation (%) | 2 (14) | 0 (0) |
| HPV positive (%) | 0 (0) | 1 (17) |
| Prior BRAF-targeted therapy | 2 | 0 |
| Prior immunotherapy (%)* | 10 (71) | 2 (33) |
| Anti-CTLA-4 | 6 (43) | 1 (17) |
| Anti-PD-1 | 6 (43) | 1 (17) |
| Anti-CTLA-4+anti-PD-1 | 1 (7) | 0 (0) |
| Interleukin-2 | 4 (29) | 0 (0) |
| Other | 7 (50) | 0 (0) |
| Prior chemotherapy | 0 (0) | 3 (50) |
| Median # prior treatments | 4 | 3 |
| Prior radiation | 7 (50) | 5 (83) |
*Most patients received multiple sequential monotherapy and combination immunotherapies.
CTLA-4, cytotoxic T lymphocyte antigen-4; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; PD-1, programmed cell death.